Lund, Sweden, August 17, 2023 - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the resignation of Malin Carlsson as the company's Chief Operating Officer (COO). Dr Carlsson will leave her role at the end of October to assume an executive role in a global pharma company. Dr Carlsson’s responsibilities will be transferred to other members of the Management team.

"We would like to thank Malin for the dedication she has shown during her time at Alligator and in particular her valuable contribution to our mitazalimab program, which is continuing to make excellent clinical progress," said Søren Bregenholt, CEO of Alligator Bioscience. "Malin's experience in immunology and drug development, and the new role she is about to embark upon, demonstrate how Alligator is able to attract talents in the biotech industry, and we wish her the very best for the future."

Alligator recently announced positive second interim results from the ongoing OPTIMIZE-1 Phase 2 study evaluating the company's lead asset mitazalimab in combination with chemotherapy, mFOLFIRINOX, in 1st line metastatic pancreatic cancer. The study continues to progress well and remains on track for top-line readout in early Q1 2024.